Clark & Stuart Inc Acquires Shares of 29,126 Organon & Co. (NYSE:OGN)

Clark & Stuart Inc bought a new position in Organon & Co. (NYSE:OGN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 29,126 shares of the company’s stock, valued at approximately $435,000.

A number of other institutional investors have also modified their holdings of the stock. Geode Capital Management LLC grew its stake in Organon & Co. by 2.0% in the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock worth $81,288,000 after purchasing an additional 82,220 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Organon & Co. by 39.8% in the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock worth $71,905,000 after buying an additional 988,336 shares during the period. Deprince Race & Zollo Inc. grew its position in shares of Organon & Co. by 6.8% during the 2nd quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company’s stock worth $70,829,000 after buying an additional 216,907 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Organon & Co. by 35.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after buying an additional 875,128 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Organon & Co. by 23.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock valued at $49,843,000 after acquiring an additional 463,216 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Trading Down 0.7 %

Shares of NYSE:OGN opened at $15.89 on Monday. The company has a market capitalization of $4.09 billion, a PE ratio of 3.15, a P/E/G ratio of 0.81 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The business’s fifty day simple moving average is $15.36 and its 200-day simple moving average is $18.37.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.78 EPS. As a group, equities research analysts predict that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 annualized dividend and a dividend yield of 7.05%. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.